Search

Displaying results 2881 - 2890 of 10000 in total
  1. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    PW2101 is a beta blocker intended for the treatment of hypertension and angina. … The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  2. Drug

    Florbetapir F-18

    go.drugbank.com/drugs/DB09149
    ApprovedInvestigational

    who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. … Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide

  3. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

  4. Drug

    Cortisone acetate

    go.drugbank.com/drugs/DB01380
    ApprovedInvestigational

    [A226295] Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory

    Categories: Corticosteroids for Systemic Use
  5. Drug

    VX-148

    go.drugbank.com/drugs/DB06103
    Experimental

    The IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes. VX-148 is a developed for the treatment of autoimmune diseases. … VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH).

  6. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency. … Cerliponase alfa is a hydrolytic lysosomal N-terminal tripeptidyl peptidase-1 (TPP1).

  7. Drug

    Minocycline

    go.drugbank.com/drugs/DB01017
    ApprovedInvestigational

    [A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: MINOCYCLIN 1A PHARMA 50MG, AA-Minocycline 50mg Capsule
  8. Drug

    Influenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16727
    ApprovedWithdrawn

    Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. … A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses.

    Synonyms: Influenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)Categories: Inactivated Influenza A Virus Vaccine
  9. Drug

    Technetium Tc-99m tilmanocept

    go.drugbank.com/drugs/DB09266
    Approved

    DTPA serves as a chelating agent for technetium Tc 99m to bind [FDA Label]. … Food and Drug Administration (FDA) for the imaging of lymph nodes with or without scintigraphic imaging.

    Products: Kit for the preparation of Lymphoseek (technetium Tc 99m tilmanocept)
  10. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. … the treatment of relapsed or refractory DLBCL in adult patients who cannot receive autologous stem cell transplants.